The FDA has approved Lialda (mesalamine), a once-daily oral formulation of mesalamine for the induction of remission in patients with active, mild-to-moderate ulcerative colitis. Lialda tablets have a pH dependent gastro-resistant coating which delays the release of the medication to the colon. Lialda is expected to be available soon.For more information call Shire at (800) 536-7878 or visit